CoChat

KIF13B establishes a CAV1-enriched microdomain at the ciliary transition zone to promote Sonic hedgehog signalling

Open access

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

Ciliary membrane composition is controlled by transition zone (TZ) proteins such as RPGRIP1, RPGRIPL and NPHP4, which are vital for balanced coordination of diverse signalling systems like the Sonic hedgehog (Shh) pathway. Activation of this pathway involves Shh-induced ciliary accumulation of Smoothened (SMO), which is disrupted by disease-causing mutations in TZ components. Here we identify kinesin-3 motor protein KIF13B as a novel member of the RPGRIP1N-C2 domain-containing protein family and show that KIF13B regulates TZ membrane composition and ciliary SMO accumulation. KIF13B is upregulated during ciliogenesis and is recruited to the ciliary base by NPHP4, which binds to two distinct sites in the KIF13B tail region, including an RPGRIP1N-C2 domain. KIF13B and NPHP4 are both essential for establishment of a CAV1 membrane microdomain at the TZ, which in turn is required for Shh-induced ciliary SMO accumulation. Thus KIF13B is a novel regulator of ciliary TZ configuration, membrane composition and Shh signalling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms14177

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Kif13b is upregulated during serum deprivation and localizes to the base and along the primary cilium. (a) Kinesins identified in a global transcriptomics analysis of up- and downregulated genes in serum-deprived relative to non-starved NIH3T3 cells. Only kinesin genes that are significantly up- or downregulated (P<0.05, two-tailed t-test; n=3) are listed. (b) Immunoblot analysis of MEFs cultured in the presence or absence of serum using mouse monoclonal KIF13B antibody #1 (see Methods for details). (c) Localization of endogenous KIF13B in serum-starved MEFs using KIF13B-specific rabbit antiserum (green) (Supplementary Fig. 1a) and antibody against acetylated α-tubulin (Ac-tub; red) to mark the cilium (closed arrow). DNA is stained with DAPI (blue). Note localization of KIF13B along the length and base (asterisk) of the cilium. (d) GFP-KIF13B (green) localization in pre-extracted RPE1 cells. GFP-KIF13B is found along the cilium (Ac-tub, blue) and at two distinct puncta at the ciliary base, flanking Pericentrin 2 (PCTN2; red). Open arrows indicate the distal end of the basal body; closed arrows show cilia. Quantitative analysis revealed that approximately 72% of the cells displayed GFP-KIF13B at the ciliary base whereas in 23% of the cells GFP-KIF13B was detected both at the ciliary base and along the axoneme (33 cells analysed in total, n=3). (e) GFP-KIF13B co-localizes with CEP164 in pre-extracted RPE1 cells. Cilia and CEP164 were stained with the indicated antibodies. Open arrows indicate the two different pools of GFP-KIF13B at the basal body; closed arrows show cilia. (f,g) Schematics of the GFP-tagged deletion constructs and IFM analysis (representative images) of their ability to localize to the centrosome, marked by p150Glued antibody (red), in non-ciliated interphase RPE1 cells. Assessment of centrosome localization, quantified in Supplementary Fig. 1h, is based on IFM analysis of at least 40 cells per construct (n=3). DNA was stained with DAPI (blue). Insets in (g) show enlarged views of the centrosome region. Scale bars: 2 μm in c; 10 μm in d,e,g.
Figure 1 Kif13b is upregulated during serum deprivation and localizes to the base and along the primary cilium. (a) Kinesins identified in a global transcriptomics analysis of up- and downregulated genes in serum-deprived relative to non-starved NIH3T3 cells. Only kinesin genes that are significantly up- or downregulated (P<0.05, two-tailed t-test; n=3) are listed. (b) Immunoblot analysis of MEFs cultured in the presence or absence of serum using mouse monoclonal KIF13B antibody #1 (see Methods for details). (c) Localization of endogenous KIF13B in serum-starved MEFs using KIF13B-specific rabbit antiserum (green) (Supplementary Fig. 1a) and antibody against acetylated α-tubulin (Ac-tub; red) to mark the cilium (closed arrow). DNA is stained with DAPI (blue). Note localization of KIF13B along the length and base (asterisk) of the cilium. (d) GFP-KIF13B (green) localization in pre-extracted RPE1 cells. GFP-KIF13B is found along the cilium (Ac-tub, blue) and at two distinct puncta at the ciliary base, flanking Pericentrin 2 (PCTN2; red). Open arrows indicate the distal end of the basal body; closed arrows show cilia. Quantitative analysis revealed that approximately 72% of the cells displayed GFP-KIF13B at the ciliary base whereas in 23% of the cells GFP-KIF13B was detected both at the ciliary base and along the axoneme (33 cells analysed in total, n=3). (e) GFP-KIF13B co-localizes with CEP164 in pre-extracted RPE1 cells. Cilia and CEP164 were stained with the indicated antibodies. Open arrows indicate the two different pools of GFP-KIF13B at the basal body; closed arrows show cilia. (f,g) Schematics of the GFP-tagged deletion constructs and IFM analysis (representative images) of their ability to localize to the centrosome, marked by p150Glued antibody (red), in non-ciliated interphase RPE1 cells. Assessment of centrosome localization, quantified in Supplementary Fig. 1h, is based on IFM analysis of at least 40 cells per construct (n=3). DNA was stained with DAPI (blue). Insets in (g) show enlarged views of the centrosome region. Scale bars: 2 μm in c; 10 μm in d,e,g.CC BY · PubMed Central
Figure 2 Identification of RPGRIP1N-C2 type domains in KIF13B and related kinesin-3 motors. (a) Schematics of the domain structure of selected RPGRIP1N-C2 domain-containing proteins identified by bioinformatics analysis. (b) Cladogram showing the evolutionary relationship of the different C2 domain families and superfamilies. DOCK-C2, CC2D2A-C2, B9-C2, NT-C2 represent PFAM C2 superfamilies. NPHP4N-C2, human NPHP4 central C2 domain (amino acids 661-756); C2CD3, human C2CD3 C-terminal C2 domain (amino acids 1,436-1,501); RPGRIP1, human RPGRIP1 RPGRIPN-C2 type domain (amino acids 609-711); RPGRIP1L, human RPGRIP1L RPGRIP1N-C2 type domain (amino acids 588-690); KIF13B-C2, human KIF13B RPGRIP1N-C2 type domain (amino acids 861-1,000). The cladogram was reconstructed using a Neighbour Joining Using PAM250 method implemented in the Jalview program under default parameters. (c) Predicted three-dimensional structure of KIF13B-C2861-1,000 compared to the solved crystal structure of the RPGRIP1N-C2 domain in RPGRIP1L (PDB: 2YRB). (d) Alignment of selected RPGRIP1N-C2 type domains identified in our bioinformatic survey. The remote C2 domain of synaptotagmin I (SYTI) is included for comparison. The defining signature of aromatic amino acids specific to the RPGRIP1N-C2 type domains are highlighted in light orange. Homologous residues other than those found in aromatic amino acid profiles are shown in blue. Secondary structure predictions as assessed by PSIPRED are shown above (predicted for KIF13B RPGRIP1N-C2 domain) and below (predicted for RPGRIP1 RPGRIP1N-C2 domain) the alignment. H, α-helix; E, β-sheet; C, random coils.
Figure 2 Identification of RPGRIP1N-C2 type domains in KIF13B and related kinesin-3 motors. (a) Schematics of the domain structure of selected RPGRIP1N-C2 domain-containing proteins identified by bioinformatics analysis. (b) Cladogram showing the evolutionary relationship of the different C2 domain families and superfamilies. DOCK-C2, CC2D2A-C2, B9-C2, NT-C2 represent PFAM C2 superfamilies. NPHP4N-C2, human NPHP4 central C2 domain (amino acids 661-756); C2CD3, human C2CD3 C-terminal C2 domain (amino acids 1,436-1,501); RPGRIP1, human RPGRIP1 RPGRIPN-C2 type domain (amino acids 609-711); RPGRIP1L, human RPGRIP1L RPGRIP1N-C2 type domain (amino acids 588-690); KIF13B-C2, human KIF13B RPGRIP1N-C2 type domain (amino acids 861-1,000). The cladogram was reconstructed using a Neighbour Joining Using PAM250 method implemented in the Jalview program under default parameters. (c) Predicted three-dimensional structure of KIF13B-C2861-1,000 compared to the solved crystal structure of the RPGRIP1N-C2 domain in RPGRIP1L (PDB: 2YRB). (d) Alignment of selected RPGRIP1N-C2 type domains identified in our bioinformatic survey. The remote C2 domain of synaptotagmin I (SYTI) is included for comparison. The defining signature of aromatic amino acids specific to the RPGRIP1N-C2 type domains are highlighted in light orange. Homologous residues other than those found in aromatic amino acid profiles are shown in blue. Secondary structure predictions as assessed by PSIPRED are shown above (predicted for KIF13B RPGRIP1N-C2 domain) and below (predicted for RPGRIP1 RPGRIP1N-C2 domain) the alignment. H, α-helix; E, β-sheet; C, random coils.CC BY · PubMed Central
Figure 3 KIF13B interacts with NPHP4 via its C2 domain and DUF region. (a) FLAG pulldown analysis of HEK293T cells co-expressing GFP-KIF13B with FLAG-NPHP4 or FLAG-RPGRIP1L. FLAG-constructs were IP'ed using anti-FLAG conjugated agarose beads and resolved proteins were subjected to immunoblot analysis with the indicated antibodies. WCE, whole cell extract. The appearance of GFP-KIF13B as a double band (top panel) is likely a consequence of protein overexpression. (b) FLAG IP of cell extracts from HEK293T cells co-expressing FLAG-NPHP4 with either GFP-KIF13B or GFP-KIF17 using anti-FLAG conjugated beads followed by immunoblotting with indicated antibodies. (c) Size exclusion chromatography of HEK293T cells co-expressing KIF13B-HA and FLAG-NPHP4 followed by immunoblot analysis with HA or FLAG antibodies. (d,e) FLAG-NPHP4 expressing HEK293T cells co-expressing GFP-tagged full-length (FL) or truncated KIF13B fusion proteins were subjected to FLAG IP followed by immunoblotting with indicated antibodies. (f) IP of HEK293T cells co-expressing GFP-KIF13B-C2861-1,000 and FLAG-NPHP4 using antibodies as indicated. (g) IFM of RPE1 cells expressing GFP-KIF13B-C2861-1,000. The insets show enlarged views of the boxed area containing the centrosome, marked by PCTN2 antibody. (h) HEK293T cells co-expressing GFP-KIF13B and truncated versions of FLAG-NPHP4, as indicated, were harvested and cell extracts subjected to FLAG IP followed by immunoblotting with indicated antibodies. (i) Diagram showing FLAG-NPHP4 deletion constructs used in h. (j) Binding assay of immuno-purified GFP (negative control) or GFP-KIF13B-C2861-1,000 mixed with bacterially purified GST fused to the central C2 domain of NPHP4 (GST-N4-C22650-839). (k) IFM analysis of Nphp4+/+ and Nphp4−/− MEFs expressing GFP-KIF13B (green). The insets show enlarged views of the boxed area containing the centrosome, marked by antibody against p150Glued (red). In all, 45-49 cells were analysed per condition (n=2). Difference in the percentage of cells with GFP-KIF13B centrosome localization obtained as mean±s.e.m. (n=2) Nphp4+/+; Nphp4−/− (88.5±3.5; 42±3) and two-tailed t-test (P<0.01). Representative IFM pictures of MEFs are shown. Scale bars: 10 μm in g,k.
Figure 3 KIF13B interacts with NPHP4 via its C2 domain and DUF region. (a) FLAG pulldown analysis of HEK293T cells co-expressing GFP-KIF13B with FLAG-NPHP4 or FLAG-RPGRIP1L. FLAG-constructs were IP'ed using anti-FLAG conjugated agarose beads and resolved proteins were subjected to immunoblot analysis with the indicated antibodies. WCE, whole cell extract. The appearance of GFP-KIF13B as a double band (top panel) is likely a consequence of protein overexpression. (b) FLAG IP of cell extracts from HEK293T cells co-expressing FLAG-NPHP4 with either GFP-KIF13B or GFP-KIF17 using anti-FLAG conjugated beads followed by immunoblotting with indicated antibodies. (c) Size exclusion chromatography of HEK293T cells co-expressing KIF13B-HA and FLAG-NPHP4 followed by immunoblot analysis with HA or FLAG antibodies. (d,e) FLAG-NPHP4 expressing HEK293T cells co-expressing GFP-tagged full-length (FL) or truncated KIF13B fusion proteins were subjected to FLAG IP followed by immunoblotting with indicated antibodies. (f) IP of HEK293T cells co-expressing GFP-KIF13B-C2861-1,000 and FLAG-NPHP4 using antibodies as indicated. (g) IFM of RPE1 cells expressing GFP-KIF13B-C2861-1,000. The insets show enlarged views of the boxed area containing the centrosome, marked by PCTN2 antibody. (h) HEK293T cells co-expressing GFP-KIF13B and truncated versions of FLAG-NPHP4, as indicated, were harvested and cell extracts subjected to FLAG IP followed by immunoblotting with indicated antibodies. (i) Diagram showing FLAG-NPHP4 deletion constructs used in h. (j) Binding assay of immuno-purified GFP (negative control) or GFP-KIF13B-C2861-1,000 mixed with bacterially purified GST fused to the central C2 domain of NPHP4 (GST-N4-C22650-839). (k) IFM analysis of Nphp4+/+ and Nphp4−/− MEFs expressing GFP-KIF13B (green). The insets show enlarged views of the boxed area containing the centrosome, marked by antibody against p150Glued (red). In all, 45-49 cells were analysed per condition (n=2). Difference in the percentage of cells with GFP-KIF13B centrosome localization obtained as mean±s.e.m. (n=2) Nphp4+/+; Nphp4−/− (88.5±3.5; 42±3) and two-tailed t-test (P<0.01). Representative IFM pictures of MEFs are shown. Scale bars: 10 μm in g,k.CC BY · PubMed Central
Figure 4 KIF13B-dependent TZ localization of CAV1 in RPE1 cells. (a) IFM using antibodies against CAV1 (red) and Ac-tub (blue) to mark the cilium (closed arrows). Open arrow marks CAV1 above the basal body (asterisk). The leftmost image is a digital interference contrast (DIC) micrograph of the cell with the nucleus stained with DAPI (pseudocoloured yellow). Insets show enlargement of the cilium-centrosome region. (b) IFM of CAV1-GFP expressing cells. Open arrow, TZ; asterisk, basal body (PCTN2; blue). (c) IFM of endogenous CAV1 (red). CEP164 (green) marks the transition fibres. (d) Cells treated with control- or KIF13B siRNA were immunoblotted and proteins detected with indicated antibodies. For KIF13B, mouse monoclonal anti-KIF13B #2 was used (see Methods). (e) CAV1 staining (red; open arrow) in ciliated cells treated with control- or KIF13B-specific siRNA. Closed arrow marks the cilium (Ac-tub, green), asterisk the centrosome (p150Glued antibody, green). (f) Quantification of CAV1 staining in control- or KIF13B-siRNA transfected cells. In all, 50-100 cells were analysed per condition (n=3). Bars: mean±s.e.m. P values result from two-way ANOVA followed by Sidak's multiple comparison (***, P≤0.001). (g) Immunoblot of control (wild type) and three KIF13B knock out clones generated using CRISPR-Cas9 technology. Clone #3 was used for further analysis and designated KIF13B−/−. For KIF13B detection, mouse anti-KIF13B #2 antibody was used (see Methods). (h) IFM of CAV1 in control (wild type) and KIF13B−/− cells. Open arrow, TZ; closed arrows, cilia. (i) Quantification of data in h. Between 5 and 20 cells were analysed per condition (n=3). Bars: mean±s.e.m. P values result from two-way ANOVA followed by Sidak's multiple comparison (****, P≤0.0001). (j) Quantification of CAV1 staining in control (wild type) and KIF13B−/− cells expressing GFP or GFP-KIF13B. Bars: mean±s.e.m. P values result from two-way ANOVA followed by Sidak's multiple comparison (*, P≤0.05; NS, not significant). Between 5 and 20 cells were analysed per condition (n=3). (k) CAV1 localization (red; open arrow) in cells expressing GFP-KIF13B or GFP-DN KIF13B (green). Closed arrow: cilium (Ac-tub; blue). Scale bars: 10 μm in a; 2 μm in b,c; 5 μm in e,h; 3 μm in k.
Figure 4 KIF13B-dependent TZ localization of CAV1 in RPE1 cells. (a) IFM using antibodies against CAV1 (red) and Ac-tub (blue) to mark the cilium (closed arrows). Open arrow marks CAV1 above the basal body (asterisk). The leftmost image is a digital interference contrast (DIC) micrograph of the cell with the nucleus stained with DAPI (pseudocoloured yellow). Insets show enlargement of the cilium-centrosome region. (b) IFM of CAV1-GFP expressing cells. Open arrow, TZ; asterisk, basal body (PCTN2; blue). (c) IFM of endogenous CAV1 (red). CEP164 (green) marks the transition fibres. (d) Cells treated with control- or KIF13B siRNA were immunoblotted and proteins detected with indicated antibodies. For KIF13B, mouse monoclonal anti-KIF13B #2 was used (see Methods). (e) CAV1 staining (red; open arrow) in ciliated cells treated with control- or KIF13B-specific siRNA. Closed arrow marks the cilium (Ac-tub, green), asterisk the centrosome (p150Glued antibody, green). (f) Quantification of CAV1 staining in control- or KIF13B-siRNA transfected cells. In all, 50-100 cells were analysed per condition (n=3). Bars: mean±s.e.m. P values result from two-way ANOVA followed by Sidak's multiple comparison (***, P≤0.001). (g) Immunoblot of control (wild type) and three KIF13B knock out clones generated using CRISPR-Cas9 technology. Clone #3 was used for further analysis and designated KIF13B−/−. For KIF13B detection, mouse anti-KIF13B #2 antibody was used (see Methods). (h) IFM of CAV1 in control (wild type) and KIF13B−/− cells. Open arrow, TZ; closed arrows, cilia. (i) Quantification of data in h. Between 5 and 20 cells were analysed per condition (n=3). Bars: mean±s.e.m. P values result from two-way ANOVA followed by Sidak's multiple comparison (****, P≤0.0001). (j) Quantification of CAV1 staining in control (wild type) and KIF13B−/− cells expressing GFP or GFP-KIF13B. Bars: mean±s.e.m. P values result from two-way ANOVA followed by Sidak's multiple comparison (*, P≤0.05; NS, not significant). Between 5 and 20 cells were analysed per condition (n=3). (k) CAV1 localization (red; open arrow) in cells expressing GFP-KIF13B or GFP-DN KIF13B (green). Closed arrow: cilium (Ac-tub; blue). Scale bars: 10 μm in a; 2 μm in b,c; 5 μm in e,h; 3 μm in k.CC BY · PubMed Central
Figure 5 CAV1 TZ localization is disrupted in cells lacking NPHP4. (a,b) IFM analysis of wild type (Nphp4+/+) and Nphp4−/− MEFs stained with CAV1 (red; open arrow) and PCTN2 (green; asterisk) antibodies. (c,d) Quantification of CAV1 staining patterns in Nphp4+/+ and Nphp4−/− MEFs (c), and in wild type and Dynll1GT/GT MEFs (d). At least 30 cells were analysed per condition (n=3). Bars represent mean±s.e.m. P values result from two-way ANOVA followed by Sidak's multiple comparison (***, P≤0.001; NS, P≥0.05, not significant). Scale bar: 5 μm.
Figure 5 CAV1 TZ localization is disrupted in cells lacking NPHP4. (a,b) IFM analysis of wild type (Nphp4+/+) and Nphp4−/− MEFs stained with CAV1 (red; open arrow) and PCTN2 (green; asterisk) antibodies. (c,d) Quantification of CAV1 staining patterns in Nphp4+/+ and Nphp4−/− MEFs (c), and in wild type and Dynll1GT/GT MEFs (d). At least 30 cells were analysed per condition (n=3). Bars represent mean±s.e.m. P values result from two-way ANOVA followed by Sidak's multiple comparison (***, P≤0.001; NS, P≥0.05, not significant). Scale bar: 5 μm.CC BY · PubMed Central
Figure 6 Defective SMO ciliary translocation and Shh signalling in KIF13B- or CAV1-deficient cells. (a) IFM showing ciliary accumulation of SMO (green) in control-siRNA transfected cells stimulated with Shh-N CM for 24 h (left panels). In KIF13B-depleted cells, Shh-N CM did not induce detectable ciliary accummulation of SMO (right panels). The cilium was stained with Ac-Tub antibody (red, arrows). (b) Quantification of the data in a. The relative fluorescence intensity of SMO ciliary staining was measured (see Methods for details) for at least 50 cells per condition (n=3). Bars represent mean±s.e.m. P values result from a two-tailed t-test (***, P≤0.001; NS, P≥0.05, not significant). (c) Relative fluorescence intensity of SMO ciliary staining in control or KIF13B-depleted cells stimulated with purmorphamine (PMA). Total number of cilia measured per condition is indicated above each column. Bars represent mean±s.e.m. (n=2). (d) Depletion of KIF13B leads to reduced GLI1 expression in Shh-N CM stimulated cells, as determined by RT-qPCR analysis. The analysis was performed on serum starved RPE1 cells treated with Shh-N CM for 24 h using B2M as a reference gene (n=3). Bars represent mean±s.e.m. P values result from a two-tailed t-test (*, P≤0.05). (e) IFM analysis of ciliary SMO staining (red) in Shh-N CM stimulated KIF13B−/− RPE1 cells expressing GFP alone or GFP-KIF13B, as indicated. The cilium is stained with Ac-tub antibody (blue, arrows). (f) Quantification of data shown in e. Bars represent mean±s.e.m. P values result from two-way ANOVA followed by Sidak's multiple comparison (***, P≤0.001; NS, P≥0.05, not significant). Between 5 and 20 cells were analysed per condition (n=3). (g,i,k) IFM analysis of Shh-N CM induced ciliary SMO (green) localization in RPE1 cells with and without treatment with MBCD (g,i) or CAV1-specific siRNA (k). The cilium and centrosome are stained with antibodies against Ac-tub (blue, arrows) and PCTN2 (red), respectively. (h,j,l) Quantification of data in (g,i,k), respectively. Between 30 and 40 cells were analysed per condition (n=3). Bars represent mean±s.e.m. P values result from two-tailed t-test (***, P≤0.001; **, P≤0.01). Scale bars: 5 μm.
Figure 6 Defective SMO ciliary translocation and Shh signalling in KIF13B- or CAV1-deficient cells. (a) IFM showing ciliary accumulation of SMO (green) in control-siRNA transfected cells stimulated with Shh-N CM for 24 h (left panels). In KIF13B-depleted cells, Shh-N CM did not induce detectable ciliary accummulation of SMO (right panels). The cilium was stained with Ac-Tub antibody (red, arrows). (b) Quantification of the data in a. The relative fluorescence intensity of SMO ciliary staining was measured (see Methods for details) for at least 50 cells per condition (n=3). Bars represent mean±s.e.m. P values result from a two-tailed t-test (***, P≤0.001; NS, P≥0.05, not significant). (c) Relative fluorescence intensity of SMO ciliary staining in control or KIF13B-depleted cells stimulated with purmorphamine (PMA). Total number of cilia measured per condition is indicated above each column. Bars represent mean±s.e.m. (n=2). (d) Depletion of KIF13B leads to reduced GLI1 expression in Shh-N CM stimulated cells, as determined by RT-qPCR analysis. The analysis was performed on serum starved RPE1 cells treated with Shh-N CM for 24 h using B2M as a reference gene (n=3). Bars represent mean±s.e.m. P values result from a two-tailed t-test (*, P≤0.05). (e) IFM analysis of ciliary SMO staining (red) in Shh-N CM stimulated KIF13B−/− RPE1 cells expressing GFP alone or GFP-KIF13B, as indicated. The cilium is stained with Ac-tub antibody (blue, arrows). (f) Quantification of data shown in e. Bars represent mean±s.e.m. P values result from two-way ANOVA followed by Sidak's multiple comparison (***, P≤0.001; NS, P≥0.05, not significant). Between 5 and 20 cells were analysed per condition (n=3). (g,i,k) IFM analysis of Shh-N CM induced ciliary SMO (green) localization in RPE1 cells with and without treatment with MBCD (g,i) or CAV1-specific siRNA (k). The cilium and centrosome are stained with antibodies against Ac-tub (blue, arrows) and PCTN2 (red), respectively. (h,j,l) Quantification of data in (g,i,k), respectively. Between 30 and 40 cells were analysed per condition (n=3). Bars represent mean±s.e.m. P values result from two-tailed t-test (***, P≤0.001; **, P≤0.01). Scale bars: 5 μm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 72

Metadata

Authors
Schou, K. B., Mogensen, J. B., Morthorst, S. K., Nielsen, B. S., Aleliunaite, A., Serra-Marques, A., Fürstenberg, N., Saunier, S., Bizet, A. A., Veland, I. R., Akhmanova, A., Christensen, S. T., & Pedersen, L. B.
Affiliations
  • University of Copenhagen (DK)
  • Utrecht University (NL)
  • Inserm (FR)
Corresponding author
Pedersen, Lotte B.
Venue
Nature Communications
Published
2017-01-30
Volume
8
Issue
1
Pages
14177-14177
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2581531657
Cited by
72
References
72
Citations by year
2026: 8 · 2025: 5 · 2024: 6 · 2023: 7 · 2022: 4 · 2021: 8 · 2020: 12 · 2019: 13 · 2018: 8 · 2017: 1
FWCI
6.16
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Funders
  • Lundbeckfonden (R54-A5375, R54-2010-5375)
  • Novo Nordisk
  • Danmarks Frie Forskningsfond (#6108-00457B, #1331-00254, 10-085373, (#09-070398)
  • Novo Nordisk Fonden (NNF15OC0016886, NNF14OC0011535)
  • H. Lundbeck A/S
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Keywords
KIF13B, caveolin-1, ciliary transition zone, Sonic hedgehog signaling, Smoothened, NPHP4, ciliogenesis, lipid rafts, primary cilia, ciliopathies
MeSH terms
Zinc Finger Protein GLI1, Smoothened Receptor, Protein Domains, Animals, Cell Line, Cell Membrane, Cilia, Gene Expression Regulation, Humans, Membrane Proteins, Proteins, Signal Transduction, Up-Regulation, Kinesins, Computational Biology, Gene Expression Profiling, NIH 3T3 Cells, Caveolin 1, Mice, Hedgehog Proteins, Gene Knockout Techniques, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.